Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Study Summary

This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.

Conditions

Advanced Malignancies NSCLC Ovarian Cancer Urothelial Cancer Solid Tumors

Interventions / Drugs

Avelumab Lorlatanib Talazoparib Pemetrexed Axitinib CMP 001 Utomilumab PF04518600

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment68 participants

Primary Completion—

Lead SponsorPfizer

Data Retrieved2026-04-11 02:55:53.190422+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.